The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients

Area of Science:

• * Oncology
• * Immunology
• * Genetic Engineering

Background:

• * Mutation-derived neoantigens are key targets in cancer immunotherapy.
• * Adoptive T cell transfer (ACT) therapy is advancing with neoantigen-specific T cell receptors (TCRs).
• * Current methods for identifying neoantigen-reactive TCRs face challenges with clinical timelines.

Purpose of the Study:

• * To provide an overview of T cell receptor (TCR) engineering strategies.
• * To describe the selection and expansion of carrier cells for TCR-ACT.
• * To discuss next-generation methods for rapid identification of TCR candidates for gene therapy.

Main Methods:

• * Review of current TCR engineering techniques.
• * Analysis of carrier cell selection and expansion protocols for ACT.
• * Exploration of emerging technologies for TCR candidate identification.

Main Results:

• * TCR engineering is central to advancing ACT.
• * Optimal carrier cell selection is crucial for ACT efficacy.
• * Rapid identification of TCR candidates is essential for clinical translation.

Conclusions:

• * Advances in TCR engineering and carrier cell selection are critical for effective ACT.
• * Novel methods are needed to accelerate the identification of neoantigen-reactive TCRs.
• * Streamlining TCR identification and gene transfer holds promise for personalized cancer immunotherapy.